Menu
The Goodman Institute Health Blog
  • Home
  • Authors
    • Devon Herrick, Ph.D.
    • John C. Goodman
  • Popular Topics
    • Artificial Intelligence and Healthcare
    • Consumer-Driven Health Care
      • Affordable Care Act
      • Cost of Healthcare
      • COVID-19 and Public Health
      • Doctors & Hospitals
      • Public Insurance
      • Policy & Legislation
    • Direct Primary Care
    • Health Economics & Costs
      • Drug Prices & Regulations
      • Health Insurance
      • Health Reform
    • Medical Tourism
    • Telemedicine
    • Medicare
      • Single-Payer/Medicare-for-All
  • Goodman Institute
  • Contact
The Goodman Institute Health Blog

Author: Devon Herrick

Study: Needle Exchanges May Do More Harm than Good

Posted on December 5, 2022 by Devon Herrick

Public health research dating back decades found that needle exchanges for intravenous drug users saved lives.

+

Internships Boost Health Care Workers in Rural CO

Posted on December 2, 2022 by Devon Herrick

I grew up in a small town in the middle of nowhere. My parents house was 19 miles East of the Colorado border. The adjacent Colorado counties were so sparsely populated that the ranches were open range. There were no fences. The local hospital where I got my tonsils removed only had 9 beds. The hospital is county-owned, as is the long-term care facility. Some of the local health care providers are subsidized by the county, with free office space and guaranteed incomes. Otherwise, the only health care providers would be miles away in other counties.

+

FDA Approves Fecal Transplants as though it were a Drug

Posted on December 1, 2022 by Devon Herrick

Clostridium difficile infections  (CDI) are difficult to treat and can be deadly. CDI is an infection of the gut when the gut bacteria are thrown out of balance and populated with Clostridium difficile rather than a healthy biome. The standard treatment is antibiotics, which can also wreck beneficial gut biome.  CDI often is recurrent, coming back time and time again.

+

New Alzheimer’s Drug May be a Breakthrough! Or a Dud!

Posted on November 30, 2022November 30, 2022 by Devon Herrick

In June of 2021 the Alzheimer’s drug, Aduhelm, was approved by the U.S. Food and Drug Administration (FDA). Aduhelm is a monoclonal antibody. It targets a specific protein in the brain that is thought to form plaques in the brains of Alzheimer’s patients, causing brain cells to atrophy and die.

+
  • Previous
  • 1
  • …
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • …
  • 169
  • Next

For many years, our health care blog was the only free enterprise health policy blog on the internet. Then, when the NCPA closed its doors, the health blog stopped as well.

During this five-year hiatus no one else has come forward to claim the space. So, my colleagues and I have decided to restart the blog in connection with the Goodman Institute. We invite you and others to use this forum to share your views.

John C. Goodman,

Visit www.goodmaninstitute.org

Subscribe via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 36 other subscribers

Popular Topics

©2025 The Goodman Institute Health Blog | Website by Lexicom